Will Cronos Group (TSX:CRON) Reach $27 This Year?

Cronos Group Inc (TSX:CRON)(NASDAQ:CRON) has been doing well this week, but investors should be careful not to get caught up in the hype surrounding the stock.

| More on:
Businessmen teamwork brainstorming meeting.

Image source: Getty Images

Cronos Group Inc (TSX:CRON)(NASDAQ:CRON) got a big boost this week when it received a vote of confidence from one analyst who put a 12-month price target of $27 on the stock, up from $17 previously. It’s a big change that’s gotten investors excited as well.

Why did Cronos get an upgrade in price?

The driver behind the increase in the price target was a result of comments made by Cronos CEO Mike Gorenstein on Tuesday at the Consumer Analyst Group of New York. He suggested that the company wasn’t too far away from making an entry into the U.S. and that it would be looking to be competitive if CBD were launched there.

The analysts believe that entering the U.S. with a strong partner like Altria could help with its expansion, thereby giving the company a big advantage.

Takeaways for investors

The fact that Cronos wants to enter the U.S. and jump in on the CBD craze there is not a big revelation. Any Canadian cannabis company would likely want to do the same, especially one with the resources of a company like Altria.

Cronos didn’t suddenly change its strategy, introduce a new product or come up with a way to suddenly improve its financials overnight. Instead, its CEO stated something that really didn’t amount to a whole lot, and yet, it was enough for an analyst to jump all over it.

The CEO didn’t offer a timeline as to when the company would enter the U.S., and so it’s an empty claim that really means little today. Unfortunately, much of the hype behind pot stocks has been driven around these vague promises of what the future might hold than of what reality is today.

CEOs have a vested interest in a company performing well and will often try to paint as rosy a picture as possible of its future. For investors, that shouldn’t be a reason to invest in a company. Investors should demand definitive numbers and timelines, not some vague expectations of what the future might hold.

Will the stock climb to $27?

Cronos is a very expensive stock given what it has achieved thus far. With just $6.5 million in its most recent quarter, the company is nowhere near its peers, yet its valuation is significantly higher. The stock is trading well into the triple digits in terms of price-to-sales ratio — an alarming level for any stock.

While I wouldn’t rule out hype pushing the price of the stock up to $27 in the near term, it would only make it that much more overpriced. Investors who buy the stock today are paying for futures and potential that may never be realized, which will create a lot of risk. Even if it were to rise to that level, I wouldn’t expect it to stay there.

The stock is not a good buy at its current price, let alone at $27. Investors would be better off looking at other, more reasonably priced pot stocks to invest in.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Are Cannabis Stocks Still a Thing in 2023?

The whole question of whether cannabis stocks are still relevant in 2023 is an interesting one. Here's my take on…

Read more »

A cannabis plant grows.
Cannabis Stocks

Why Canopy Growth Stock Fell 72% Last Year

Canopy Growth stock is a beaten-up cannabis giant that is trading at a discount compared to historical multiples. But is…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is SNDL Stock a Buy in January 2023?

SNDL is among the worst-performing cannabis stocks in the last three years. But is SNDL stock a buy right now?

Read more »

a person watches a downward arrow crash through the floor
Cannabis Stocks

Why Tilray Stock Fell Almost 60% in 2022

Tilray is a Canadian cannabis stock that is down 93% from all-time highs. Let's see if TLRY stock is a…

Read more »